Regeneron Pharmaceuticals


SKU: REGN Category:


This is our first report on biopharma major, Regeneron which is off to a great start in 2022. The company has shown a decent performance in terms of the top-line growth as well as margins, beating Wall Street expectations in the last quarter. Revenues increased by 25% when Covid-19 antibody cocktail research contributions were excluded, reflecting their increasingly diversified core businesses continued success. Global net sales for EYLEA increased 11% to almost $2.4 billion in Q1, outpacing the growth of the anti-VEGF category in the United States by $1.5 billion. After more than ten years, Regeneron recently passed 50 million EYLEA injections globally, marking yet another significant milestone for the drug and demonstrating its well-proven efficacy and safety profile. The management continues to increase shareholder value through prudent capital allocation, including roughly $350 million in share repurchases in the first three months of this year. Overall, we believe Regeneron is well-positioned to deliver sustainable growth and long-term value creation because of their long-term prospects for their business and productive pipeline. We initiate coverage on the stock with a ‘Hold’ rating.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!